Emmanuel Papadakis
Stock Analyst at Deutsche Bank
(1.52)
# 3,061
Out of 4,817 analysts
41
Total ratings
47.37%
Success rate
-0.17%
Average return
Main Sectors:
Stocks Rated by Emmanuel Papadakis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $95 → $150 | $104.87 | +43.03% | 9 | Sep 19, 2024 | |
| MRNA Moderna | Upgrades: Hold | $85 → $80 | $25.74 | +210.80% | 8 | Aug 6, 2024 | |
| GRFS Grifols | Downgrades: Sell | n/a | $7.17 | - | 2 | Mar 12, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $67.87 | - | 3 | Feb 8, 2024 | |
| ALVO Alvotech | Maintains: Hold | $8 → $12 | $8.33 | +44.06% | 2 | Mar 7, 2023 | |
| SNY Sanofi | Upgrades: Hold | n/a | $51.85 | - | 4 | Aug 12, 2022 | |
| NVO Novo Nordisk | Upgrades: Buy | n/a | $59.91 | - | 4 | Mar 16, 2022 | |
| CVAC CureVac | Initiates: Hold | $35 | $3.19 | +997.18% | 1 | Oct 22, 2021 | |
| NVS Novartis AG | Downgrades: Sell | n/a | $111.41 | - | 3 | Sep 20, 2021 | |
| ARGX argenx SE | Initiates: Hold | n/a | $599.86 | - | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $36.63 | - | 4 | Feb 4, 2021 |
BioNTech SE
Sep 19, 2024
Maintains: Buy
Price Target: $95 → $150
Current: $104.87
Upside: +43.03%
Moderna
Aug 6, 2024
Upgrades: Hold
Price Target: $85 → $80
Current: $25.74
Upside: +210.80%
Grifols
Mar 12, 2024
Downgrades: Sell
Price Target: n/a
Current: $7.17
Upside: -
AstraZeneca
Feb 8, 2024
Downgrades: Hold
Price Target: n/a
Current: $67.87
Upside: -
Alvotech
Mar 7, 2023
Maintains: Hold
Price Target: $8 → $12
Current: $8.33
Upside: +44.06%
Sanofi
Aug 12, 2022
Upgrades: Hold
Price Target: n/a
Current: $51.85
Upside: -
Novo Nordisk
Mar 16, 2022
Upgrades: Buy
Price Target: n/a
Current: $59.91
Upside: -
CureVac
Oct 22, 2021
Initiates: Hold
Price Target: $35
Current: $3.19
Upside: +997.18%
Novartis AG
Sep 20, 2021
Downgrades: Sell
Price Target: n/a
Current: $111.41
Upside: -
argenx SE
Jul 23, 2021
Initiates: Hold
Price Target: n/a
Current: $599.86
Upside: -
Feb 4, 2021
Downgrades: Sell
Price Target: n/a
Current: $36.63
Upside: -